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A 
 
 ORIGINAL ARTICLE  
   
Effects of Perceived Treatment on Quality of Life 
and Medical Outcomes in a Double-blind 
Placebo Surgery Trial 
Cynthia McRae, PhD; Eva Cherin, MA; T. Gayle Yamazaki, PhD; Gretchen Diem, PhD; Alexander H. Vo, PhD; 
Dan Russell, PhD; J. Heiner Ellgring, PhD; Stanley Fahn, MD; Paul Greene, MD; Sandra Dillon, RN; 
Hal Winfield, RN; Kimberly B. Bjugstad, PhD; Curt R. Freed, MD 
 
 
 
 
Context: This study was part of a large double-blind sham 
surgery–controlled trial designed to determine the effec- 
tiveness of transplantation of human embryonic dopa- 
mine neurons into the brains of persons with advanced 
Parkinson’s disease. This portion of the study investi- 
gated the quality of life (QOL) of participants during the 
1 year of double-blind follow-up. 
 
Objectives: To determine whether QOL improved more 
in the transplant group than in the sham surgery group 
and to investigate outcomes at 1 year based on per- 
ceived treatment (the type of surgery patients thought 
they received). 
 
Design: Participants were randomly assigned to re- 
ceive either the transplant or sham surgery. Reported re- 
sults are from the 1-year double-blind period. 
 
Setting: Participants were recruited from across the 
United States and Canada. Assessment and surgery were 
conducted at 2 separate university medical centers. 
 
Participants: A volunteer sample of 40 persons with 
idiopathic Parkinson’s disease participated in the trans- 
plant (“parent”) study, and 30 agreed to participate in 
the related QOL study: 12 received the transplant and 
18 received sham surgery. 
 
Interventions: Interventionsintheparentstudyweretrans- 
plantation and sham brain surgery. Assessments of QOL were 
made at baseline and 4, 8, and 12 months after surgery. 
 
Main Outcome Measures: Comparison of the actual 
transplant and sham surgery groups and the perceived 
treatment groups on QOL and medical outcomes. We also 
investigated change over time. 
 
Results: There were 2 differences or changes over time 
in the transplant and sham surgery groups. Based on per- 
ceived treatment, or treatment patients thought they re- 
ceived, there were numerous differences and changes over 
time. In all cases, those who thought they received the 
transplant reported better scores. Blind ratings by medi- 
cal staff showed similar results. 
 
Conclusions: The placebo effect was very strong in this 
study, demonstrating the value of placebo-controlled sur- 
gical trials. 
 
Arch Gen Psychiatry. 2004;61:412-420 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Author affiliations are listed 
at the end of this article. 
 
RELATIVELY NEW EXPERI- 
mental approach to treat- 
ing Parkinson’s disease 
(PD) is the stereotactic im- 
plantation of human em- 
bryonic dopamine neurons into the brains 
of persons with severe PD. Unblinded clini- 
cal trials1-21 have shown that this surgical 
procedure ameliorates some of the symp- 
toms of the disease and that the trans- 
planted dopamine neurons survive. Very 
little research has focused on subjective 
changes in quality of life (QOL) that may 
result from the surgery.21 
To assess the efficacy of fetal trans- 
plant surgery, the procedure was sub- 
jected to a double-blind sham surgery– 
 
controlled trial, with half the patients 
receiving the transplant and half receiv- 
ing sham surgery.22 The study design not 
only included the unusual condition of 
sham surgery, but it also maintained the 
double-blind phase for 1 year, a very long 
time for placebo-controlled trials.23 These 
conditions combined to provide unique 
opportunities to investigate the effects of 
sham surgery as well as the benefits of 
transplant surgery and to determine the ef- 
fects of a 12-month double-blind trial. One 
of the primary goals of the “parent” study 
was to determine whether the signs and 
symptoms of PD improved more in trans- 
plant recipients than in those who re- 
ceived the sham surgery. Similarly, one of 
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the goals of this (QOL) study was to determine whether 
QOL improved more in the transplant group than in the 
sham surgery group. A related goal was to investigate out- 
comes at 1 year based on perceived treatment, or the type 
of surgery patients thought they received. The final goal 
of this study was to examine medical outcomes based on 
actual as well as perceived treatment to determine whether 
perceived treatment was related to ratings by medical staff 
at 12 months. 
 
 METHODS  
  
A complete description of the parent study can be found in the 
article by Freed et al.22 The following subsections describe the 
methods of the QOL study. 
 
PATIENTS 
 
Forty persons from across the United States and Canada were 
recruited to participate in this double-blind surgical trial. Twenty 
patients were randomly assigned to receive the fetal tissue trans- 
plant and 20 patients were randomly assigned to the sham sur- 
gery condition. Patients were told that those in the sham sur- 
gery group would have the option of receiving the transplant 
after the blind was lifted. Inclusion criteria for the study were 
(1) a diagnosis of idiopathic PD of at least 7 years’ duration; 
(2) a continuing response to the administration of levodopa, 
the principal drug used to treat PD; and (3) the presence of an 
intractable problem, such as “off” periods, dyskinesias, or “freez- 
ing” not controlled by dopamine agonist therapy. Exclusion cri- 
teria included (1) obvious depression or cognitive impair- 
ment (as assessed by a neuropsychologist), (2) previous brain 
surgery, or (3) the presence of diabetes mellitus, severe car- 
diopulmonary disease, other severe medical disease, or mag- 
netic resonance imaging evidence of cerebrovascular disease. 
After rigorous screening, patients who were accepted into the 
parent study were invited to participate in the QOL portion of 
the project. Thirty patients agreed to participate. All neuro- 
logic examinations were performed at Columbia-Presbyterian 
Medical Center (CPMC). 
 
QOL Evaluation of Patients 
 
Quality of life is a multidimensional construct that was mea- 
sured using a variety of widely recognized, commonly used in- 
struments focusing on 3 fundamental aspects of QOL: Physi- 
cal, Emotional, and Social functioning. Data were collected by 
sending questionnaires to patients 1 week after scheduled evalu- 
ation visits to CPMC. Participants were asked to respond to the 
questionnaire and return it in the postage-paid envelope pro- 
vided. Patients were paid $25 for each completed question- 
naire. The response rate was 98%. The scales contributing to 
each aspect of QOL are presented in the following subsec- 
tions. 
 
Physical Functioning. Unified Parkinson’s Disease Rating Scale 
(patient version). This scale24 is an adaptation of the physician 
version of the Unified Parkinson’s Disease Rating Scale 
(UPDRS) that is uniformly used to rate the physical function- 
ing abilities and problems of patients with PD.25 The patient 
version was developed for a health promotion program that 
was disseminated through the mail.24 Four primary subscales 
were used in this version of the UPDRS: Activities of Daily 
Living (ADLs) at “best” and “worst” and Severity of Symp- 
toms at “best” and “worst.” Correlations of the patient version 
with a variety of the UPDRS subscale scores rated by medical 
staff range from r = 0.58 to r = 0.71.26 Because previous re- 
sults22 have shown that scores “off” medications provide a 
more valid assessment of patient status, only the “off” scores 
(worst) from the patient UPDRS were included in the com- 
posite variable. Lower scores indicate better outcomes. The 
estimate of reliability (Cronbach’s a) for the “worst” scores 
was .84 at baseline. 
“Free or Restricted”. This single, global item measures how 
free or restricted the person feels “in doing what you want to 
do.” A Likert scale ranging from 1 (I still do everything I want 
to do) to 7 (I can no longer do the things I want to do) is used. 
Lower scores indicate better outcomes. 
 
Emotional Functioning. Parkinson’s Disease Stress Scale. This 
scale was developed for use with German patients with PD and 
is available to interested readers on request (J. H. Ellgring, PhD, 
M. Macht, PhD, R. Schwarz, MA, unpublished data, 1993). The 
scale has 19 items, with lower scores indicating less stress. Cron- 
bach’s a for the scale was .77. 
Center for Epidemiologic Studies–Depression Scale. This 
scale27 is a 20-item self-report measure of depressive symp- 
toms. Each item is rated on a 4-point scale related to fre- 
quency; for example, 0 indicates “less than 1 day” and 3 indi- 
cates “5 to 7 days.” Lower scores indicate fewer depressive 
symptoms. The estimate of reliability (Cronbach’s a) was .89. 
State-Trait Anxiety Inventory. The “State” version28 of this 
well-validated instrument was designed to assess the current, 
situational aspects of anxiety. The 20 items are rated on a 4-point 
scale ranging from 1 (not at all) to 4 (very much). Lower scores 
indicate less anxiety. Cronbach’s a for the scale was .89. 
Intrusiveness of Illness Scale. This scale29 is an adaptation of 
one designed to measure the degree to which a chronic illness 
interferes with usual life activities. A scale ranging from 1 (very 
little) to 7 (a great deal) was used for each item. Lower scores 
on this 17-item scale indicate less intrusiveness of illness. The 
estimated reliability of the scale (Cronbach’s a) was .88. 
 
Social Functioning. Social Provisions Scale. This 24-item scale30 
assesses perceived social support. Each item is rated on a 4-point 
scale ranging from 1 (strongly disagree) to 4 (strongly agree). 
Lower scores indicate less perceived support. The reliability es- 
timate (Cronbach’s a) at baseline was .91. 
Social Contact. A measure of social contact was devel- 
oped for this study to assess the amount of social interaction 
or activity experienced by each participant. Three items assess- 
ing frequency of socializing with friends, telephone commu- 
nication, and participation in public activities were scored on 
a 6-point scale ranging from 1 (not at all) to 6 (every day). Lower 
scores indicate less social contact. Estimated reliability (Cron- 
bach’s a) was .69 at baseline. 
 
Medical Evaluation of Patients 
 
Patients were evaluated at the Irving Center for Clinical 
Research at CPMC twice before surgery and 4, 8, and 12 
months after surgery. Each assessment lasted 3 to 4 days, 
allowing for evaluations on and off medications. Each patient 
was followed by a neurologist and by 1 of 2 research nurses 
(S.D. and H.W.) throughout the study. Medical staff were 
unaware of treatment group assignment for the duration of the 
study. 
 
Global Rating Scale. The primary outcome variable of the par- 
ent study was a single item representing a subjective global rat- 
ing of change in severity of disease.22 Possible scores ranged 
from –3 (much worse since surgery) to +3 (much improved since 
surgery). One week before the follow-up evaluations at 4, 8, 
and 12 months, patients filled out global ratings of their health 
status relative to their condition just before surgery. Medical 
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staff completed the same evaluation at each patient visit. No 
reliability or validity information is available for this scale. 
 
Perceived Surgery. Seven days after surgery and 1 week be- 
fore the follow-up evaluations at 4, 8, and 12 months, patients 
were asked to indicate whether they thought they received the 
transplant or sham surgery. These evaluations were mailed to 
patients by the staff at CPMC. Evaluations were returned to the 
biostatistician at CPMC and were not revealed to the medical 
staff. 
 
Unified Parkinson’s Disease Rating Scale. The UPDRS25 is a 
standard instrument used to assess various aspects of PD, in- 
cluding motor performance, muscle rigidity, tremor, speech, 
and gait. Lower scores indicate better performance. The UPDRS 
has high interrater31 and test-retest32 reliability. 
 
Schwab and England Activities of Daily Living Scale. The 
Schwab and England33 assesses ability to perform activities of 
daily living on a scale ranging from 0% to 100%, with higher 
scores indicating more normal performance. Descriptive 
anchors for the scale are presented in increments of 10, for 
example, 100, 90, 80, etc. This is a standard assessment 
instrument in PD and has well-established reliability and 
validity.31 
 
Hoehn and Yahr. The Hoehn and Yahr34 is the standard dis- 
ease staging scale for PD. Scores range from 0 (no signs of dis- 
ease) to 5 (wheelchair bound or bedridden unless aided). Lower 
scores indicate fewer signs of disease. High interrater reliabil- 
ity between neurologists, patients, and caregivers has been 
found.35 
For the purpose of this study, “off” medications was de- 
fined as before administration of the first morning dose of le- 
vodopa and at least 12 hours after the last administration of 
levodopa the previous day.36 As noted earlier, only “off” scores 
were included in data analyses. Patients and medical person- 
nel completed the Global Rating Scale, the Schwab and En- 
gland, and the Hoehn and Yahr at each assessment period. The 
standard version of the UPDRS was completed only by medi- 
cal personnel. 
 
TRANSPLANTATION   METHOD 
 
All patients had a stereotactic frame attached to the head for 
magnetic resonance imaging to establish the coordinates for 
the needle tracks for implantation of the tissue. Four burr 
holes were drilled bilaterally in the forehead to accommodate 
the needles. Patients were awake during the procedure. Scalp 
incisions and twist drill holes were done under local anesthe- 
sia. Both groups received identical preoperative evaluation 
and intraoperative sedation and pain control. For patients in 
the transplant group, implants were made into the putamen 
with embryonic mesencephalic tissue containing dopamine 
neurons. Each needle pass into the putamen contained tissue 
from a single embryo. Four embryos were used for the 4 sites 
implanted. Needles for participants in the placebo condition 
remained empty and did not penetrate the brain. No patient 
received immunosuppressive therapy. The dialogue during 
the surgery was limited and unscripted. Additional informa- 
tion related to the surgery can be found in the article by Freed 
et al.22 
from r =0.30 to r = 0.75. Relationships among the Emotional 
functioning variables ranged from r = 0.63 to r = 0.77. Reliabili- 
ties of the linear composites for these constructs at baseline and 
at 4, 8, and 12 months ranged from 0.72 to 0.89. The 2 vari- 
ables predicted to constitute Social functioning did not corre- 
late highly enough to be combined into one composite mea- 
sure. Neither was the reliability of the linear composite high 
enough to justify combining the variables. Therefore, mea- 
sures of perceived Social Support (Social Provisions Scale) and 
Social Contact were analyzed separately. For the composite vari- 
ables (Physical and Emotional functioning), scores for each mea- 
sure were standardized at each period based on the mean and 
standard deviation of the measure at baseline. Standard scores 
for each measure were then combined to create a total z score 
representing the composite variable. 
Phi coefficients were calculated to determine the relation- 
ship between actual and perceived treatment at 7 days and at 
4, 8, and 12 months. Independent samples t tests were used to 
examine differences between the transplant and sham surgery 
groups and between the perceived treatment groups on the 3 
QOL constructs at each time. t Tests were also used to com- 
pare the same groups on the medical outcome variables. The 
repeated-measures generalized estimating equation was used 
to examine change over time. Based on the assumption that char- 
acteristics of each person are correlated over time, all obser- 
vations (baseline and 4, 8, and 12 months) were entered si- 
multaneously into these analyses. Analysis of variance techniques 
were used to examine differences in change scores. All P val- 
ues are 2-tailed. No adjustments were made for multiple com- 
parisons because of the exploratory nature of the analyses and 
because there are no comparable data from other studies. 
 
 RESULTS  
  
The demographic information for the 30 participants in 
the QOL portion of the study is presented in Table 1. 
There were no statistically significant differences be- 
tween the transplant and sham groups on demographic 
characteristics or QOL variables at baseline. 
Membership in the perceived treatment groups 
changed at each period as patients’ perceptions of which 
treatment they received changed over time. Table 2 in- 
dicates the type of surgery patients thought they re- 
ceived at each period as well as the surgery they actually 
received. Results show that 22 (76%) of 29 participants 
thought they had received the transplant 7 days after the 
procedure. Based on presurgical interviews, this finding 
seems to reflect the belief of most patients that they would 
be among those who received the transplant initially. This 
number was reduced to 10 (33%) of 30 participants 12 
months later. Phi coefficients, which measure the rela- 
tionship between dichotomous variables, ranged from 0.00 
to 0.15 and were not statistically significant, indicating 
no relationship between the type of treatment patients 
actually received and what they thought they received 
at any follow-up period. 
 
DIFFERENCES AND CHANGES 
IN QOL VARIABLES 
 
STATISTICAL  ANALYSIS 
 
Preliminary analyses were performed to determine relation- 
ships among the variables predicted to form the 3 aspects of 
QOL. Correlations for the Physical functioning variables ranged 
The results in this section are presented in 2 parts. First, 
results related to actual transplant and sham surgery 
groups are presented, followed by results related to per- 
ceived treatment groups, or the type of surgery patients 
thought they received. 
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Table 2. Relationships Between Actual 
and Perceived Treatment 
 
Perceived Treatment 
Actual Treatment Transplant 
7 d (Phi = 0.15) 
Sham Surgery 
Transplant 
Sham surgery 
 
Transplant 
Sham surgery 
4 mo (Phi = 0.00) 
8 
12 
8 mo (Phi = −0.06) 
4 
7 
12 mo (Phi = 0.00) 
4 
6 
4 
6 
 
8 
11 
Transplant 
Sham surgery 
8 
12 
0.4 
 
0.2 
 
0 
 
–0.2 
 
–0.4 
 
–0.6 
 
–0.8 
 
–1.0 
 
–1.2 
 
–1.4 
Baseline 4 mo 8 mo 12 mo 
Time 
 
Table 1. Baseline Characteristics of Participants  
 
Characteristic 
Transplant  Group 
(n = 12) 
Sham Surgery Group 
(n = 18) 
Total 
(n = 30) 
Sex, No. (%)    
F 7 (58) 8 (44) 15 (50) 
M 5 (42) 10 (56) 15 (50) 
Age, mean ± SD, y 59.9 ± 7.9 56.3 ± 10.4 57.8 ± 9.5 
Education, mean ± SD, y 16.6 ± 2.8 16.3 ± 2.2 16.4 ± 2.4 
Duration of disease, mean ± SD, y 15.5 ± 6.6 16.0 ± 3.6 15.7 ± 5.0 
Married or living with partner, No. (%) 10 (83) 10 (56) 20 (67) 
Annual income >$40000, No. (%) 9 (75) 10 (56) 19 (63) 
Currently employed, No. (%) 3 (25) 4 (22) 7 (23) 
Family history of PD, No. (%) 1 (8) 4 (22) 5 (17) 
Other chronic health problems, No. (%) 5 (42) 2 (11) 7 (23) 
Currently smoke, No. (%) 0 1 (6) 1 (3) 
Ever smoke, No. (%) 2 (17) 7 (39) 9 (30) 
Ethnicity, No. (%)    
Asian 1 (8) 0 1 (3) 
Black 0 1 (6) 1 (3) 
Hispanic 0 1 (6) 1 (3) 
White 11 (92) 16 (89) 27 (90) 
Abbreviation: PD, Parkinson’s disease. 
 
 
 
 
 
 
Figure 1. Mean changes in Physical functioning quality of life from baseline 
to 12 months: actual surgery. Decreased scores indicate improvement. Error 
bars represent SEM. 
 
Perceived Treatment Groups 
 
Actual Treatment Groups 
 
Results from analyses at baseline and 4, 8, and 12 months 
indicated that the only significant difference between the 
transplant and sham surgery groups was in Social Con- 
tact at 4 months, with the sham surgery group reporting 
more social contact (P =.03). 
Using repeated-measures analyses to examine change 
over time, there was a significant improvement in Physi- 
cal functioning in both groups over 12 months (P =.01) 
(Figure 1). There was also a significant timeX treatment 
interaction for Physical functioning between the 2 groups 
over the 4 assessment periods (P =.04). As can be seen 
in Figure 1, marked improvement from baseline to 4 
months was seen in the transplant group. There was a 
downward linear trend indicating improvement over time 
in the sham surgery group. 
When analyses were conducted based on perceived treat- 
ment groups, or the treatment patients thought they re- 
ceived at each assessment period, there were several dif- 
ferences between the groups, all favoring the perceived 
transplant group (Table 3). At 8 and 12 months, those 
who believed they received the transplant reported bet- 
ter Physical functioning than those who thought they re- 
ceived the sham surgery (P = .02 and P = .03, respectively). 
Social Support at 8 months (P =.01) and 12 months 
(P =.03) was better for those who thought they received 
the transplant vs the sham surgery. 
Using repeated-measures analyses and based on per- 
ceived treatment at 12 months, there was improvement 
in Physical functioning over time in the perceived groups 
(P =.01) (Figure 2). A significant interaction between 
time and perceived group was found for Social Support 
(P = .05), with those who thought they received the sham 
Transplant Group 
Sham Surgery Group 
Transplant 10 2 
Sham surgery 12 5 
 
z 
Sc
or
e 
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–0.2 
 
–0.4 
 
–0.6 
 
–0.8 
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*Scores for composite variables are standardized (z scores), given as mean (SD). Lower scores indicate better functioning. 
†Scores for Social Support and Social Contract are raw scores, given as mean (SD), because they are not composite variables. Higher scores indicate more 
social support or contact. 
‡P<.05. 
§P<.01. 
 
 
 
 
 
 
Figure 2. Mean changes in Physical functioning quality of life from baseline 
to 12 months: perceived surgery. Decreased scores indicate improvement. 
Error bars represent SEM. 
 
 
surgery reporting less support at 8 and 12 months than 
those who thought they received the transplant. 
 
DIFFERENCES AND CHANGES 
ON MEDICAL EVALUATION 
 
To reduce the number of comparisons, and thus the pos- 
sibility of type I error, only statistical analyses using the 
baseline and 12-month assessments were conducted. 
 
Actual Treatment Groups 
 
On ratings by medical staff, there were no differences be- 
tween the transplant and sham surgery groups at 12 
months on the Global Rating Scale, UPDRS and its sub- 
scales, Schwab and England, or Hoehn and Yahr rat- 
ings. Likewise, there were no differences between groups 
on medical variables rated by patients (ie, Global Rating 
Scale, Schwab and England, and Hoehn and Yahr). 
Among medical staff, statistically significant changes 
over time (baseline to 12 months) were found for 2 vari- 
ables. First, ratings for transplant and sham surgery groups 
improved for UPDRS tremor scores in the “off” state 
(P =.01). Second, an interaction effect was found on the 
UPDRS rigidity “off” scores (P =.04), with the trans- 
plant group improving and the sham surgery group get- 
ting worse. There were no changes over time in pa- 
tients’ self-report ratings of the medical variables. 
 
Perceived Treatment Groups 
 
Although blind as to the type of treatment patients ac- 
tually received, medical personnel reported several dif- 
ferences based on the type of treatment patients thought 
they received at 12 months. Results presented in Table 4 
show statistically significant differences on several clini- 
cal ratings based on patients’ perceived treatment. Pa- 
tient ratings of medical variables also showed statisti- 
cally significant differences (Table 4). In all cases, results 
were better for those who thought they received the trans- 
plant vs the sham surgery. 
In medical staff ratings, there were several changes 
over time (baseline to 12 months) based on perceived 
treatment or the treatment patients thought they re- 
ceived at 12 months (Table 5). Similar to the actual 
treatment groups, medical personnel rated both per- 
ceived groups as improving on the UPDRS tremor “off” 
(P =.02). On all other measures listed in Table 5, inter- 
action effects indicated that the perceived transplant 
group was getting better and that the perceived sham 
surgery group was getting worse. Regarding patient rat- 
ings given in Table 5, patients who believed they re- 
ceived the transplant at 12 months showed improve- 
ment in global rating scores over time, whereas those in 
the perceived sham group showed a decline in scores 
(P<.001). 
These results are somewhat different from those 
reported for the parent study22 because of the difference 
in sample size (n= 39 in the parent study, with 19 per- 
sons receiving transplants, vs n= 30 in the QOL study, 
with only 12 receiving transplants). In the parent 
study,22 there was a significant difference in improve- 
ment (change scores) in UPDRS motor “off” scores be- 
tween the actual transplant and sham surgery groups 
(P =.04). As shown in Figure 3, differences in im- 
provement for the perceived treatment groups were also 
significant (P<.05). In the parent study, scores for 
Schwab and England “off” improved significantly more 
for the actual transplant group than for the actual sham 
group over 12 months (P =.04), as did scores for the 
perceived transplant group relative to the perceived 
sham surgery group (P<.01). Because no statistically 
Transplant Group 
Sham Surgery Group 
Table 3. Differences Between Perceived Groups in Quality-of-Life (QOL) Dimensions 
4 mo 8 mo 12 mo 
QOL Dimension 
Physical functioning* 
Emotional functioning* 
Social Support† 
Social Contact† 
Transplant 
(n = 19) 
−0.41 (0.85) 
0.15 (0.75) 
80 (8.0) 
13 (3.2) 
Sham Surgery 
(n = 10) 
−0.24 (1.00) 
−0.47 (0.85) 
77 (9.8) 
12 (3.6) 
Transplant 
(n = 11) 
−0.84 (0.69)‡ 
−0.13 (0.65) 
83 (7.9)§ 
14 (2.9) 
Sham Surgery 
(n = 19) 
0.06 (1.03) 
0.40 (0.96) 
74 (9.1) 
12 (3.2) 
Transplant 
(n = 10) 
−0.84 (0.54)‡ 
−0.24 (0.68) 
85 (9.9)‡ 
14 (2.2) 
Sham Surgery 
(n = 19) 
−0.17 (0.98) 
0.14 (0.74) 
77 (9.5) 
12 (2.9) 
z 
Sc
or
e 
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Abbreviation: UPDRS, Unified Parkinson’s Disease Rating Scale. 
*Data are given as mean (SD). 
 
 
Abbreviation: UPDRS, Unified Parkinson’s Disease Rating Scale. 
*Scores represent change from baseline to 12 months. 
†Time contrast is significant. 
‡Interaction contrast is significant. 
 
significant interactions were found in these analyses, 
results indicate that actual and perceived treatment had 
independent effects on the outcomes. 
 
 COMMENT  
  
One of the primary goals of this study was to determine 
whether QOL improved more in the transplant group than 
in the sham surgery group during the 1-year period of 
the double-blind study. There was only one statistically 
significant difference between the transplant and sham 
surgery groups in terms of QOL. Results of compari- 
sons at 4, 8, and 12 months revealed a difference in So- 
cial Contact at 4 months, with the transplant group re- 
porting less social interaction than the sham surgery 
group. Both groups showed statistically significant im- 
provement in Physical functioning during 12-month fol- 
low-up (Figure 1). These results, therefore, do not indi- 
cate statistically significant improvement in QOL in the 
transplant group over the sham surgery group by the end 
of the initial phase of the study. 
The reasons for the transplant group reporting less 
social interaction are unclear. This result may reflect a 
type I error, or it may be related to the subtle but pro- 
longed recovery period reported by some patients who 
received the transplant.37 Regarding both groups report- 
ing improvement in Physical functioning (Figure 1), it 
is possible that hope or optimism contributed to those 
results. Individuals desperate enough for relief from symp- 
toms to risk the conditions of this study may have been 
inclined to imagine themselves getting better over time, 
particularly when they did not really know what “get- 
ting better” might look or feel like. 
Because the study involved the unusual element of 
sham surgery and the double-blind phase lasted approxi- 
mately 13 months, one of the goals of the study was to 
investigate the effect of perceived treatment on QOL out- 
comes. Results indicated that the sustained improve- 
ment in Physical functioning from 4 to 12 months among 
the perceived transplant group (Figure 2) was accom- 
panied by relatively stable scores in Emotional function- 
ing and Social Support over time (both of these re- 
mained in the same range as normative scores throughout 
the 12 months) (Table 3). Conversely, the perceived sham 
surgery group improved only slightly in Physical func- 
tioning over time (Figure 2) and subsequently declined 
Table 5. Changes From Baseline to 12 Months: Perceived Groups 
Variable 
Transplant  Group 
(n = 10) 
Medical Staff Ratings* 
Sham Surgery Group 
(n = 20) P Value 
UPDRS score 
Tremor “off” −1.0 −1.0 .02† 
Total “off” −10.5 2.1 .006‡ 
Motor “off” −6.2 1.8 .008‡ 
Bradykinesia “off” −3.7 1.6 .001‡ 
Gait “off” −1.3 1.2 .004‡ 
Pull test “off” -0.5 0.3 .02‡ 
Hoehn and Yahr “off” score −0.2 0.3 .04‡ 
Schwab and England “off” score 11.4 −4.8 .004‡ 
Patient Ratings* 
Global Rating Scale score 1.9 −0.7 <.001‡ 
Table 4. Differences Between Perceived Treatment Groups at 12 Months* 
Variable 
Transplant  Group 
(n = 10) 
Medical Staff Ratings 
63.0 (12.2) 
1.3 (1.2) 
Sham Surgery Group 
(n = 20) P Value 
Schwab and England “off” score 
Global Rating Scale score 
UPDRS score 
Walking “off” 
Gait “off” 
Pull test “off” 
45.8 (21.6) 
−0.1 (1.1) 
.03 
<.01 
2.7 (1.3) 
4.5 (2.6) 
1.0 (0.9) 
Patient Ratings 
2.1 (1.1) 
1.8 (1.2) 
5.0 (2.8) 
8.4 (4.1) 
2.3 (1.4) 
.01 
<.01 
.01 
Hoehn and Yahr score 
Global Rating Scale score 
3.3 (0.7) 
−1.3 (1.2) 
<.01 
<.001 
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Figure 3. Mean changes in Unified Parkinson’s Disease Rating Scale 
(UPDRS) motor “off” scores (baseline to 12 months) for the total group in 
the parent study (n= 39). Increased scores indicate improvement. Error bars 
represent SEM. 
 
in Emotional functioning and Social Support at 8 months, 
with a slight improvement by 12 months (Table 3). Over- 
all, results indicated that perceived treatment was more 
strongly related to outcome for the duration of the 12- 
month double-blind study than was the actual treat- 
ment they received, with perceived transplant patients 
consistently reporting better QOL than the perceived sham 
surgery group. Thus, it seems that the placebo effect was 
very strong. 
The final goal of this study was to examine differ- 
ences and changes over time in medical outcomes based 
on actual and perceived treatment. There were no dif- 
ferences on the medical variables as rated by medical staff 
or patients at 12 months based on actual treatment in the 
subset of 30 patients. By contrast, the parent study showed 
statistically significant improvement in UPDRS motor “off” 
scores and Schwab and England “off” scores in trans- 
plant patients, with no change in sham surgery pa- 
tients.22 
When analyses were performed based on per- 
ceived treatment, several differences on medical vari- 
ables at 12 months were found (Table 4). All differ- 
ences, as rated by medical staff and patients, indicated 
that those who thought they received the transplant were 
doing better than those who thought they received the 
sham surgery. Analyses using data from the total group 
of 39 patients (1 patient died in a car accident before the 
12-month evaluation) produced similar results, wherein 
medical staff rated the perceived transplant group as per- 
forming statistically significantly better than the per- 
ceived sham group. 
Regarding changes over time, most were the result 
of interaction effects wherein those who thought they re- 
ceived the transplant improved and those who thought 
they underwent sham surgery got worse (Table 5). Simi- 
lar results were found in analyses including the total group 
of participants in the parent study, that is, interaction ef- 
fects were found. 
These results suggest that expectancy regarding 
which type of treatment patients received had a statisti- 
cally significant effect not only on subjective param- 
eters (Emotional functioning and Social Support) but also 
on motor symptoms (Physical functioning). The effects 
on motor symptoms were also recognized by the medi- 
cal staff, as shown in their clinical ratings (Tables 4 and 
5 and Figure 3). Whether staff ratings of motor symp- 
toms were affected by mood and other subjective expres- 
sions of the patients (similar to a “halo” effect) cannot 
be determined in this study. An alternative explanation 
is that actual changes in physical functioning led pa- 
tients to believe that they got the transplant (or not) and 
resulted in changes in ratings by the medical staff. 
Similar results related to the placebo effect have been 
found in other studies with patients with PD.38-40 These 
results underscore the need for placebo controls in stud- 
ies evaluating treatment for PD as the placebo effect seems 
to be very strong in this disease. 
In terms of the larger issue of the expectancy or pla- 
cebo effects, results suggest that the possible effective- 
ness of double-blind conditions in some studies may be 
longer than previously believed. The average length of 
time of a double-blind trial is 8 weeks.23 The double- 
blind in this study was effectively maintained for 12 
months. It seems plausible that because effects of the sur- 
gery were not predictable or definitive over the period 
of the double-blind, patients did not have clear cues as 
to which surgery they had received. Research41-43 indi- 
cates that the more extreme the placebo treatment is in 
a clinical trial, the more susceptible participants are to 
the placebo effect, or believing that they are being helped 
by the sham medication or condition. Because this study 
involved brain surgery, arguably an extreme placebo treat- 
ment, and results were not clearly discerned by patients 
or staff for the double-blind period, it seems that condi- 
tions were favorable for evoking a strong placebo re- 
sponse in this study. Although this study did not in- 
clude a standard care group that did not intend to receive 
the surgery, which would have provided the most rigor- 
ous test of the effects of transplant surgery, these results 
are consistent with a strong placebo effect. 
The lack of relationship between actual and per- 
ceived treatment throughout the study underscores sev- 
eral important points. First, it indicates the success of the 
conditions of the sham surgery. Surgical staff perform- 
ing the surgeries seem to have been convincing in their 
presentation of the placebo treatment (Table 2). Sec- 
ond, the shift from 22 persons (76%) believing that they 
got the transplant at 7 days to only 10 (33%) at 12 months 
indicates that optimism or hope may have influenced per- 
ceptions early in the study. The percentage of persons 
thinking that they received the transplant was similar in 
the parent study: 28 (72%) at 7 days and 14 (36%) at 12 
months. What contributed to the change in ratings dur- 
ing the 12-month period is beyond the scope of this ar- 
ticle. We speculate that it may have been perceived 
changes in physical condition, lack of perceived changes, 
or diminished optimism as results of the study failed to 
meet expectations. 
In summary, there were more differences and 
changes over time in QOL among perceived treatment 
groups than among actual treatment groups. Medical staff, 
who did not know which treatment each patient re- 
ceived, also reported more differences and changes at 12 
months based on patients’ perceived treatment than on 
Perceived Treatment Group 
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actual treatment. These results suggest that patients’ per- 
ceptions influenced their behavior, which in turn re- 
sulted in ratings among medical staff that paralleled pa- 
tients’ self-ratings. It is also possible that subtle changes 
in physical functioning influenced patients’ perceptions, 
which then influenced behavior. These data cannot be used 
to determine causal relationships among these indicators 
of improvement. However, the results clearly show that 
improvement, or lack of improvement, was not solely de- 
termined by actual treatment at this point in the study. 
Analyses based on the type of surgery patients thought they 
received produced results that have implications for re- 
search related to double-blind placebo-controlled trials and 
the length of time a blind can be maintained. 
Although the sham surgery research design is cur- 
rently regarded as somewhat controversial and has raised 
some important ethical concerns,44 the investigators of 
the parent study determined that the scientific benefits 
of this design outweighed potential ethical consider- 
ations. The results of this study demonstrate the impor- 
tance of a double-blind design to distinguish the actual 
and perceived values of a treatment intervention. 
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 Correction  
   
Error in Figure. In the Original Article titled “Effects of Perceived Treatment on Quality of Life and Medical Outcomes in a 
Double-blind Placebo Surgery Trial” published in the April issue of the ARCHIVES (2004;61:412-420), an incorrect version of 
Figure 3 was published. Figure 3 is published correctly here. Online versions of this article on the Archives of General Psy- 
chiatry Web site were corrected on April 13, 2004. The ARCHIVES regrets the error. 
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Figure 3. Mean changes in Unified Parkinson’s Disease Rating Scale 
(UPDRS) motor “off” scores (baseline to 12 months) for the total group in 
the parent study (n= 39). Increased scores indicate improvement. Error bars 
represent SEM. 
 
